Search company, investor...

Avanir Pharmaceuticals

Founded Year



Acq - P2P | Acquired

Total Raised






About Avanir Pharmaceuticals

AVANIR Pharmaceuticals is a biopharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need. The Company develops treatments for pseudobulbar affect, diabetic peripheral neuropathic pain, and other conditions. AVANIR out-licensed its moniclonal antibodies, and produces an over-the-counter treatment for cold sores.

Headquarters Location

30 Enterprise Suite 400

Aliso Viejo, California, 92656,

United States


Missing: Avanir Pharmaceuticals's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Avanir Pharmaceuticals's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Avanir Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Avanir Pharmaceuticals is included in 1 Expert Collection, including Diabetes.



1,902 items

Avanir Pharmaceuticals Patents

Avanir Pharmaceuticals has filed 34 patents.

The 3 most popular patent topics include:

  • Neurological disorders
  • Psychiatric diagnosis
  • Cognitive disorders
patents chart

Application Date

Grant Date


Related Topics




Morphinans, Amines, Phenols, Piperidines, NMDA receptor antagonists


Application Date


Grant Date



Related Topics

Morphinans, Amines, Phenols, Piperidines, NMDA receptor antagonists



Latest Avanir Pharmaceuticals News

Bribery in the Pharmaceutical Industry — Avanir Pharma

Nov 10, 2022

To embed, copy and paste the code into your website or blog: <iframe frameborder="1" height="620" scrolling="auto" src="//" style="border: 2px solid #ccc; overflow-x:hidden !important; overflow:hidden;" width="100%"></iframe> We always focus on foreign bribery — the FCPA and corporate bribery of foreign officials. It is certainly a problem that undermines economic development and human rights. However, bribery and corruption is real and significant in the United States, from local to state to federal government officials, the news is filled with instances of bribery and corruption. Wherever there is money flowing, there is sure to be fraud and corruption. Even outside government institutions, various industries suffer from bribery and corruption — particularly the drug industry and their interactions and relationships with physicians. A drug company (like medical device companies) can sink or swim depending on the support they get from physicians — whether the doctors will write prescriptions for their patients. As a result, here is a profound grasp of the obvious — drug companies face high-risk when dealing with doctors. In a recent announcement, DOJ announced two resolutions on an ongoing investigation focused on Avanir Pharmaceuticals and its neurological drug, Nuedexta. Specifically, Dr. Deepak Raheja, a neurologist, and Frank Mazzucco, a company sales representative, pleaded guilty on the eve of their trial to a scheme to bribe doctors to prescribe Nuedexta. Both defendants admitted to a bribery scheme in which Mazzucco arranged to pay bribes to Dr. Raheja and other doctors to write more prescriptions for Nuedexta, even for patients who did not suffer from the condition the drug treated. Between 2011 and 2016, Avanir paid Raheja around $331,000 in bribes in exchange for 10,088 prescriptions of Nuedexta (the highest in the United States). In addition to paying Raheja, Mazzucco arranged with an employee to incentivize other physicians to increase the number of prescriptions. Nuedexta is used to treat pseudobular, a condition that causes involuntary and frequent crying and laughing fits, and is often associated with patients who suffer strokes. As part of the plea deals, Raheja agreed to serve 2.5 years in prison, surrender his license and pay a fine up to $300,000 and $1.18 million in restitution. Mazzucco agreed to serve between 15 to 21 months and payment of $488,000 in restitution. These last two deals, however, is the end of a long and tortured prosecution of corruption that permeated Avanir’s Nuedexta over the last three years.

Avanir Pharmaceuticals Frequently Asked Questions (FAQ)

  • When was Avanir Pharmaceuticals founded?

    Avanir Pharmaceuticals was founded in 1988.

  • Where is Avanir Pharmaceuticals's headquarters?

    Avanir Pharmaceuticals's headquarters is located at 30 Enterprise, Aliso Viejo.

  • What is Avanir Pharmaceuticals's latest funding round?

    Avanir Pharmaceuticals's latest funding round is Acq - P2P.

  • How much did Avanir Pharmaceuticals raise?

    Avanir Pharmaceuticals raised a total of $66.18M.

  • Who are the investors of Avanir Pharmaceuticals?

    Investors of Avanir Pharmaceuticals include Otsuka Holdings, OrbiMed Advisors, Clarus, Vivo Capital, ProQuest Investments and 23 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.